Brazil's threat to break patents on anti-AIDS drugs constitutes stealing and should be opposed, not encouraged, by Congress, argues Robert Goldberg, director of the Manhattan Institute's Center for Medical Progress. Meanwhile, Brazil's health minister encouraged other countries to use WTO rules on intellectual property that in some circumstances allow the manufacturing of generic versions of patented drugs to deal with a public-health crisis.

Related Summaries